Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy
Journal of Immunology Research · 2026-01 · 2026 (1)
DOI: 10.1155/jimr/7864229 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Immunology Research, online erschienen am 16.02.2026. Verfasst von Jhommara Bautista und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador, udla.edu.ec. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Neoplasms, Tumor Microenvironment. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 238 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad de Las Américas Ecuador.
Abstract (Originalsprache)
Immunotherapy has reshaped the oncology landscape by enabling the immune system to recognize and eliminate malignant cells. Although immune checkpoint inhibitors (ICIs) targeting cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), programmed cell death‐1 (PD‐1), and programmed death‐ligand 1 (PD‐L1) have achieved durable responses in several cancers, their therapeutic benefit remains limited to a subset of patients, largely due to immune evasion, tumor heterogeneity, and immunosuppressive features of the tumor microenvironment (TME). This review comprehensively examines the expanding landscape of next‐generation immune checkpoints, encompassing both co‐inhibitory (lymphocyte activation gene‐3 [LAG‐3], T cell immunoglobulin and mucin‐domain containing‐3 [TIM‐3], TIGIT, VISTA, and IGSF8) and co‐stimulatory (ICOS, OX40, GITR, 4‐1BB, CD40, and CD27) pathways that collectively regulate the balance between immune activation and tolerance. We discuss their molecular mechanisms, translational rationale, and emerging clinical evidence, highlighting their potential to reinvigorate antitumor immunity, particularly in ICI‐refractory settings. Beyond checkpoint modulation, we explore complementary strategies aimed at remodeling the TME and enhancing immune responsiveness, including targeting immunometabolic pathways (IDO1 and CD73), innate immune sensing (toll‐like receptors [TLRs]), cytokine signaling (IL‐2), micronutrient immunoregulators (vitamin D), and the gut microbiota. The integration of these approaches into rational combination regimens, guided by predictive features such as T cell infiltration, tumor mutational burden (TMB), and microbiome composition, holds promise for extending the clinical impact of immunotherapy across malignancies. We further advocate for a precision immuno‐oncology framework that leverages multiomic profiling, systems biology, and artificial intelligence (AI) to optimize therapeutic selection and mitigate immune‐related toxicities. Emerging advances in nanomedicine, synthetic biology, and chronotherapy offer additional opportunities to enhance therapeutic specificity and durability, collectively charting a path from mechanistic insight to clinical translation toward realizing the full curative potential of cancer immunotherapy. Trial Registration: ClinicalTrials.gov identifier: LAG‐3 (NCT03470922, NCT04082364, NCT05064059, NCT05352672, NCT02614833, NCT03625323, NCT01968109), TIM‐3 (NCT03307785, NCT03680508, NCT02608268, NCT02817633), TIGIT (NCT03563716), VISTA (NCT02671955, NCT02812875), IGSF8 (NCT05669430), CD73 (NCT02503774), B7‐H3 (NCT02475213, NCT01391143, NCT02628535, NCT03406949, NCT00089245, NCT01099644, NCT01502917), OX40 (NCT01862900, NCT02315066, NCT02410512, NCT02221960, NCT02528357, NCT02923349, NCT02705482), CD27 (NCT02335918, NCT02924038, NCT02302339, NCT02386111, NCT02543645), 4‐1BB (NCT01307267, NCT02444793, NCT01471210, NCT02253992, NCT02554812), CD40 (NCT02588443, NCT03329950), ICOS (NCT02904226, NCT02723955, NCT03251924), GITR (NCT02583165, NCT02132754, NCT02697591, NCT03126110, NCT02740270, NCT02598960, NCT01239134, NCT02628574), IDO1 (NCT02752074, NCT02658890, NCT02077881, NCT01560923, NCT02073123, NCT02327078, NCT02178722), TLRs (NCT02556463, NCT02042781), and IL‐2–based therapies (NCT02869295, NCT02983045)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador, udla.edu.ec.
- Department of Medicine, New York University Grossman School of Medicine, New York, USA, med.nyu.edu.
- Jefe de servicio de oncología, Hospital Metropolitano de Quito, Quito, Ecuador.
- Hospital General Universitario Dr. Balmis, Alicante, Spain.
- Cancer Research Group, Faculty of Engineering and Applied Sciences, Universidad de Las Américas, Quito, Ecuador, udla.edu.ec.
- Center for Hematology and Regenerative Medicine, Department of Medicine Huddinge, Karolinska Institute, Stockholm, Sweden, ki.se.
ORCID-Profile: Jhommara Bautista, Andrés López-Cortés
Förderung
- Universidad de Las Américas Ecuador
Zitieren
APA
Bautista, J., Echeverría, C. E., Maldonado-Noboa, I., Adatty-Molina, J., Suárez Urresta, S., Coral-Riofrio, E. C., Araujo-Abad, S., Kyriakidis, N. C., & López-Cortés, A. (2026). Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy. Journal of Immunology Research, 2026(1). https://doi.org/10.1155/jimr/7864229
Vancouver
Bautista J, Echeverría CE, Maldonado-Noboa I, Adatty-Molina J, Suárez Urresta S, Coral-Riofrio EC, et al. Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy. Journal of Immunology Research. 2026;2026(1). doi:10.1155/jimr/7864229
BibTeX
@article{Bautista2026,
author = {Bautista, Jhommara and Echeverría, Carolina E and Maldonado-Noboa, Iván and Adatty-Molina, Joseth and Suárez Urresta, Salomé and Coral-Riofrio, Emily C and Araujo-Abad, Salomé and Kyriakidis, Nikolaos C and López-Cortés, Andrés},
title = {Next‐Generation Immune Checkpoints and Tumor Microenvironment Modulation in Cancer Immunotherapy},
journal = {Journal of Immunology Research},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/jimr/7864229}
}
EUVIMED